Revive Therapeutics Ltd
Company Profile
Business description
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.
Contact
82 Richmond Street East
The Canadian Venture Building
TorontoONM5C 1P1
CANT: +1 888 901-0036
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2025
Employees
3
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.70 | 38.30 | 0.45% |
| CAC 40 | 7,910.49 | 0.00 | 0.00% |
| DAX 40 | 24,122.40 | 86.29 | 0.36% |
| Dow JONES (US) | 41,908.87 | 768.37 | -1.80% |
| FTSE 100 | 8,786.46 | 5.34 | 0.06% |
| HKSE | 23,827.78 | 146.30 | 0.62% |
| NASDAQ | 18,907.20 | 235.52 | -1.23% |
| Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
| NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
| S&P 500 | 5,855.15 | 85.31 | -1.44% |
| S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
| SSE Composite Index | 3,387.57 | 7.10 | 0.21% |